EGFR overexpression in malignant pleural mesothelioma: An immunohistochemical and molecular study with clinico-pathological correlations
- 28 February 2006
- journal article
- Published by Elsevier BV in Lung Cancer
- Vol. 51 (2), 207-215
- https://doi.org/10.1016/j.lungcan.2005.10.016
Abstract
No abstract availableThis publication has 31 references indexed in Scilit:
- Testing for HER2 in breast cancerHistopathology, 2004
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences of the United States of America, 2004
- Akt Phosphorylation and Gefitinib Efficacy in Patients With Advanced Non-Small-Cell Lung CancerJNCI Journal of the National Cancer Institute, 2004
- Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomiesThe Journal of Thoracic and Cardiovascular Surgery, 2004
- Pemetrexed (ALIMTA), A Novel Multitargeted Antineoplastic AgentClinical Cancer Research, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibThe New England Journal of Medicine, 2004
- Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markersLaboratory Investigation, 2004
- Gefitinib in Pretreated Non–Small-Cell Lung Cancer (NSCLC): Analysis of Efficacy and Correlation With HER2 and Epidermal Growth Factor Receptor Expression in Locally Advanced or Metastatic NSCLCJournal of Clinical Oncology, 2003
- Epidermal Growth Factor Receptor Dependence in Human Tumors: More Than Just Expression?The Oncologist, 2002